Top Markets
Coin of the day
TherapeuticsMD, Inc. TherapeuticsMD, Inc.

TherapeuticsMD, Inc.

TXMD
Rang in aandelen #28925
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to... TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Aandeelprijs
$2.06
Marktkapitalisatie
$23.84M
Verandering (1 dag)
2.49%
Verandering (1 jaar)
77.59%
Land
US
Handel TherapeuticsMD, Inc. (TXMD)

Categorie

P/S-ratio voor TherapeuticsMD, Inc. (TXMD)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van TherapeuticsMD, Inc. is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor TherapeuticsMD, Inc. van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten